PSMA I&T GMP grade
PSMA I&T (TFA salt)
Precursor for radiometal-labelled PSMA I&T
Prostate-specific membrane antigen for imaging & therapy
Molecular Weight:
1497.5 [g/mol] (m.i.),
1498.4 [g/mol] (av.)
Molecular Formula: C63H92IN11O23
PSMA I&T (GMP Grade)
General Information
| Product no.: | 50009, 50107 |
| Product name: | PSMA I&T (TFA salt) |
| Synonyms: | (R)-DOTAGA-(I-y)fk(Sub-KuE) |
| Sequence: | Suber-1-oyl-ε-(DOTA-GA-3-iodo-D-Tyr-D-Phe-D-Lys-OH)-8-oyl-ε-(HO-Glu-CO-Lys-OH) |
| Molecular weight: | 1497.5 [g/mol] (m.i.), 1498.4 [g/mol] (av.) |
| Molecular formula: | C63H92IN11O23 |
| CAS no.: | 2647371-60-4 |
Product Description
Labelling precursor for [68Ga], [177Lu] and [225Ac].
For use by qualified personnel only.
Quantity
Product No. 50009: 250 µg net peptide (lyophilisate, TFA salt)
Product No. 50107: 1000 µg net peptide (lyophilisate, TFA salt)
Packaging
Clear tubular glass vials type I (borosilicate, 2 mL) with lyophilisation stoppers and closed with aluminium caps.
Storage and Stability
Storage at -20°C (± 5°C) and protected from light.
A temperature increase up to +25ºC (± 2ºC) over a period of 10 days and to +40ºC (± 2ºC) over a period of 3 days does not significantly affect the purity of the chemical precursor.
Certificates
Certificate of Analysis
Certificate of Compliance
TSE/BSE Statement on request
Manufactured in full compliance with current GMP requirements. Specifications according to Pharm. Eur. 2902 “Chemical precursors for radiopharmaceutical preparations”.
Literature
[1] Weineisen M. et al. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. J Nucl Med, 2015, 56(8):1169-76.
[2] Fendler WP. et al. 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.Eur J Nucl Med Mol Imaging, 2017, 44(6):1014-1024.
[3] Kulkarni HR et al. PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013. J Nucl Med. 2016, 57(Suppl 3):97S-104S.
[4] von Eyben FE. et al. Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. Eur J Nucl Med Mol Imaging, 2018, 45(3):496-508.
